Medicines Access Review — Implementation

No formal announcement of progress against the ten recommendations of the 2025 Medicines Access Review has been published during May 2026. DoH NI Consultations A DoH NI consultation opened on 11 May 2026 relating to proposed changes to UK-wide medicines legislation governing the definition of gene therapies, led by the MHRA. This is not directly […]

EU HTA Milestone — First Joint Clinical Assessment

The NCPE published on 4 May 2026 that the HTA Coordination Group approved the first-ever Joint Clinical Assessment report under the EU HTA Regulation. The NCPE Ireland acted as lead assessor, working with IQWiG Germany as co-assessor. The assessment covered tovorafenib (Ojemda®), an anticancer medicine for paediatric low-grade glioma. The report has been forwarded to […]